GenSight reveals positive results from RESCUE Phase III trial of GS010
Category: #health  By Mateen Dalal  Date: 2019-09-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

GenSight reveals positive results from RESCUE Phase III trial of GS010

Leber Hereditary Optic Neuropathy (LHON) is a hereditary form of vision loss that usually begins at teenage or in the early twenties. With few rare cases likely to occur in late adulthood or early childhood, various biotech firms are focusing on developing novel therapies to fight this clinical disorder.

GenSight Biologics S.A., a biotechnology company based in France is said to be developing a LHON treatment drug which is currently in the clinical stage. The firm, which is determined on developing and discovering advanced gene therapies for central nervous system disorders and retinal neurodegenerative diseases, recently revealed its first set of findings from Week 96 of the RESCUE Phase III studies.

According to sources, the study evaluated the efficacy and safety of a single intravitreal injection of GS010 in 39 patients who lost their vision due to 11778-ND4 LHON (Leber Hereditary Optic Neuropathy), which was initiated 6 months earlier to the study treatment.

Reportedly, the results point to the continuous efficiency of the drug following two years of injection, with BCVA (best-corrected visual acuity) sustaining a clinical improvement over nadir. Patient’s subjected to GS010 regained more than two-thirds of the initial loss arising in the very acute phase of the disease, further reinforcing the durability of improvement witnessed in previous readouts of the pilot.

According to Bernard Gilly, Co-Founder and Chief Executive Officer, GenSight, these results show the lasting difference that GS010 can deliver to patients who otherwise would be blind due to LHON. 

He claims that these results will be discussed with the regulatory authorities in a meeting, and effectively form a convincing core for the non-clinical and clinical data that backs its marketing authorization application in Europe.

Prior to this news, GenSight had revealed the finding from the REVERSE Phase III studies of GS010 which were shown at the 14th Meeting of the EUNOS (European Neuro-Ophthalmology Society), held in Portugal.

Reportedly, Dr. Valerio Carelli, MD, Ph.D., the Principal Investigator of the REVERSE trial and an expert on molecular and cellular mechanisms behind the mitochondrial flaws in LHON, had presented the findings at the EUNOS meeting.

Source Credit: https://www.gensight-biologics.com/2019/09/23/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-iii-clinical-trial-of-gs010-for-the-treatment-of-leber-hereditary-optic-neuropathy-lhon/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...